Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 36.18

-4.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	11/22/2004 1:45:42 PM
	of 566

So much for R803. Good thing they have back up compounds. The stock is holding up well. >>SOUTH SAN FRANCISCO (AP) -- Rigel Pharmaceuticals Inc. said Monday a clinical study showed its R803 hepatitis treatment did not significantly reduce viral levels in patients infected with the Hepatitis C virus. Shares of Rigel were sharply lower in early trading on the Nasdaq, falling $1.13, or 4.5 percent, to $24.26. Hepatitis C is an inflammation of the liver caused by the hepatitis C virus. In the study, patients were divided into eight groups, with each group receiving an increasing dose of R803 or increasing number of days of treatment. Subjects received the drug or a placebo for two to four days, plus the morning dose on the following day. "There was a decline in viral levels over the course of treatment and viral levels rose after dosing was discontinued," Rigel said. "However, the decline in viral levels was not statistically significant or clinically meaningful." Rigel said the Phase I/II clinical study of R803, an oral hepatitis C RNA polymerase inhibitor, did show that the drug was well-tolerated with no significant adverse effects. Rigel said it has continued to develop delivery approaches of R803 that it believes allow the drug to be better absorbed in the body. The company also said it believe it has identified drug candidates with better absorption rates and good antiviral activity for its hepatitis C program. The company will further discuss the program at an analyst meeting on Dec. 1. << snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next